First Copy of J&J’s $6 Billion Arthritis Drug Wins EMA Backing

First Copy of J&J’s $6 Billion Arthritis Drug Wins EMA Backing

Johnson & Johnson via Bloomberg

Remicade is J&J’s top-selling product.